📊 CBLL Key Takeaways
Investment Thesis
Ceribell exhibits strong revenue growth (+36.1% YoY) with exceptional gross margins (87.9%), indicating solid market demand and pricing power in the electromedical device sector. However, the company is unprofitable at the operating level (-65.6% margin) with significant cash burn (-$41.6M FCF), and without clear visibility to profitability, the company is consuming cash reserves despite strong balance sheet liquidity. The divergence between revenue growth and operating losses suggests execution challenges or heavy investment phase, requiring demonstrated progress toward profitability within 12-18 months to validate the business model.
CBLL Strengths
- Strong revenue growth of 36.1% YoY indicating market traction and demand
- Exceptional gross margin of 87.9% demonstrating pricing power and operational efficiency at manufacturing level
- Fortress balance sheet with $40.5M cash, 9.73x current ratio, and zero debt providing runway for operations
CBLL Risks
- Severe operating losses (-$65.6% margin) with negative net income of -$53.4M indicating unsustainable unit economics
- Significant cash burn of -$41.6M in FCF despite positive revenue, depleting cash reserves at current burn rate within ~1 year
- Heavy opex structure relative to revenue suggests sales, R&D, or administrative costs are not scaling with gross profit growth
- No visibility to path to profitability with continued negative operating cash flow and operating margin deterioration risk
Key Metrics to Watch
- Operating margin trajectory and path to breakeven (target: positive operating income within 4 quarters)
- Operating cash flow and free cash flow burn rate (critical: must improve toward positive FCF)
- Gross margin sustainability and operating expense growth rate relative to revenue growth acceleration
- Cash runway and burn rate (at current burn: ~1 year of operations remaining with $40.5M cash)
CBLL Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 9.73x current ratio provides a solid financial cushion.
CBLL Profitability Ratios
CBLL vs Healthcare Sector
How Ceribell, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CBLL Balance Sheet & Liquidity
CBLL 5-Year Financial Trend
5-Year Trend Summary: Ceribell, Inc.'s revenue has grown significantly by 36% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.39 indicates the company is currently unprofitable.
CBLL Growth Metrics (YoY)
CBLL Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $17.2M | -$8.5M | $-0.37 |
| Q2 2025 | $15.3M | -$8.5M | $-0.38 |
| Q1 2025 | $14.4M | -$8.5M | $-0.36 |
| Q3 2024 | $11.6M | -$6.2M | $-1.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CBLL Capital Allocation
CBLL SEC Filings
Access official SEC EDGAR filings for Ceribell, Inc. (CIK: 0001861107)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CBLL
What is the AI rating for CBLL?
Ceribell, Inc. (CBLL) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CBLL's key strengths?
Strong revenue growth of 36.1% YoY indicating market traction and demand. Exceptional gross margin of 87.9% demonstrating pricing power and operational efficiency at manufacturing level.
What are the risks of investing in CBLL?
Severe operating losses (-$65.6% margin) with negative net income of -$53.4M indicating unsustainable unit economics. Significant cash burn of -$41.6M in FCF despite positive revenue, depleting cash reserves at current burn rate within ~1 year.
What is CBLL's revenue and growth?
Ceribell, Inc. reported revenue of $89.1M.
Does CBLL pay dividends?
Ceribell, Inc. does not currently pay dividends.
Where can I find CBLL SEC filings?
Official SEC filings for Ceribell, Inc. (CIK: 0001861107) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CBLL's EPS?
Ceribell, Inc. has a diluted EPS of $-1.46.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.